2017-11-162016-08-26DIAS, Kris Simone Tranches. Síntese e avaliação farmacológica de novos híbridos feruloil-donepezil, planejados como candidatos a fármacos para a doença de Alzheimer. 2016. 150 f. Tese (Doutorado em Química) - Universidade Federal de Alfenas, Alfenas, MG, 2016.https://repositorio.unifal-mg.edu.br/handle/123456789/1049With the increase in average life expectancy, Alzheimer’s disease (AD) has attracted great attention, once it is a severe, progressive, disabling and incurable neurodegenerative disease. Nowadays, the available treatment for AD are limited and unable to interrupt the course of the disease. The multifactorial pathogenesis of AD hampers the development of new pharmacological approaches that aim specific targets, since there is great diversity of factors influencing the initiation and progression of the disease. The present work describes the synthesis of feruloyl-donepezil hybrids with potential to act in the therapeutic targets involved in AD and acts as acetylcholinesterase (AChE), antioxidant, anti-inflammatory and neuroprotective. The hybrids were evaluated in the inhibition assay of AChE through Ellman's method, and the 3 most active compounds of the series, PQM-130 (27a), PQM-131 (27b) and PQM-132 (27c), were selected for evaluation in direct and indirect antioxidant assays, metal chelating, anti-inflammatory and neuroprotective agents. Based on data from in vitro and in vivo, the PQM-130 (27a) was identified as promising candidate for multitarget drug to treatment of DA, because had IC50 of 0.46 uM in the assay of AchE. In silico data showed that this compound keeps a quite similar conformation than that observed for the AChE-donepezil docked complex, retaining several key interactions. Kinetic studies revealed that PQM-130 (27a) is a non-competitive AChE inhibitor, interacting with the PAS region of the enzyme with a Ki of 1.04 μM. Besides being a potent AChE inhibitor, PQM-130 (27a) also displayed a high indirect antioxidant activity in neuronal SH-SY5Y cells by activation of endogenous neuroprotective mechanisms such as Nrf2 and transcription of cytoprotective gene. PQM-130 (27a) was also able to counteract the ROS formation elicited by Fenton reaction with either Cu2+ or Fe2+ and H2O2 in neuronal SH-SH5Y cells, suggesting the ability of the compound to chelate these biometals. Furthermore, in vitro results with neuronal cells suggested that PQM-130 (27a) has neuroprotective effects against the late neuronal death elicited by Aβ1-42 oligomers. Inflammatory in vivo assays revealed a significant anti-inflammatory activity for PQM-130 (27a), being capable to reduce the inflammatory process induced in different animal models, with evidences that its mechanism of action involve inhibition of COX and LOX expression.application/pdfAcesso Abertohttp://creativecommons.org/licenses/by-nc-nd/4.0/Alzheimer, Doenças de.CurcuminaQuímica - SinteseQUIMICA ORGANICA::SINTESE ORGANICATeseViegas Júnior, Cláudio